Shanghai Labway Clinical Laboratory Co., Ltd (SHE:301060)
China · Delayed Price · Currency is CNY 10.97
+0.27 (2.52%)
Sep 1, 2026, 3:04 PM CST
SHE:301060 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 4,264 | 3,686 | 3,634 | 5,323 | 7,854 | 13,910 | |
Market Cap Growth | 7.65% | 1.45% | -31.73% | -32.23% | -43.54% | - |
Enterprise Value | 3,703 | 3,239 | 3,446 | 5,270 | 7,890 | 13,408 |
Last Close Price | 10.70 | 9.06 | 8.74 | 12.75 | 18.47 | 32.46 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 81.41 | - | - | - | 12.72 | 68.24 |
PS Ratio | 3.33 | 2.55 | 2.09 | 3.18 | 1.87 | 7.82 |
PB Ratio | 2.60 | 2.24 | 2.00 | 2.69 | 3.46 | 8.48 |
P/TBV Ratio | 2.80 | 2.43 | 2.24 | 3.06 | 3.86 | 9.15 |
P/FCF Ratio | 12.80 | 17.52 | 26.01 | 35.94 | - | 132.95 |
P/OCF Ratio | 11.09 | 13.71 | 16.80 | 9.73 | 93.32 | 62.23 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 2.89 | 2.24 | 1.98 | 3.15 | 1.88 | 7.54 |
EV/EBITDA Ratio | 37.65 | 41.70 | 1764.19 | - | 6.96 | 39.56 |
EV/EBIT Ratio | 129.56 | 217.51 | - | - | 7.37 | 45.58 |
EV/FCF Ratio | 11.12 | 15.40 | 24.67 | 35.58 | - | 128.15 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.07 | 0.10 | 0.15 | 0.21 | 0.11 | 0.04 |
Debt / EBITDA Ratio | 1.16 | 1.90 | 17.59 | - | 0.21 | 0.19 |
Debt / FCF Ratio | 0.34 | 0.82 | 1.96 | 2.75 | - | 0.63 |
Net Debt / Equity Ratio | -0.39 | -0.36 | -0.30 | -0.23 | -0.18 | -0.43 |
Net Debt / EBITDA Ratio | -7.39 | -7.57 | -283.98 | 4.27 | -0.37 | -2.09 |
Net Debt / FCF Ratio | -1.94 | -2.79 | -3.97 | -3.06 | 2.89 | -6.76 |
Asset Turnover | 0.55 | 0.59 | 0.62 | 0.50 | 1.44 | 0.99 |
Inventory Turnover | 3.30 | 3.84 | 4.18 | 3.50 | 8.95 | 7.72 |
Quick Ratio | 3.37 | 2.73 | 2.68 | 2.31 | 2.07 | 3.88 |
Current Ratio | 4.05 | 3.30 | 3.25 | 2.83 | 2.40 | 4.28 |
Return on Equity (ROE) | 3.46% | -0.89% | -5.19% | -7.61% | 37.78% | 18.12% |
Return on Assets (ROA) | 0.77% | 0.38% | -1.39% | -2.89% | 22.88% | 10.28% |
Return on Invested Capital (ROIC) | 1.78% | -1.88% | -4.47% | -9.21% | 62.87% | 29.38% |
Return on Capital Employed (ROCE) | 1.60% | 0.80% | -3.10% | -7.20% | 45.90% | 17.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 0.91% | -0.83% | -3.01% | -2.66% | 7.86% | 1.47% |
FCF Yield | 7.81% | 5.71% | 3.84% | 2.78% | -1.86% | 0.75% |
Dividend Yield | 1.57% | 1.99% | 2.29% | - | 1.62% | 0.92% |
Payout Ratio | 211.12% | - | - | - | 20.35% | 0.15% |
Buyback Yield / Dilution | 41.16% | 5.18% | -0.19% | -1.00% | -13.63% | -0.02% |
Total Shareholder Return | 42.73% | 7.16% | 2.10% | -1.00% | -12.01% | 0.91% |